** Drug developer Eton Pharmaceuticals' ETON.O shares fall 2.2% to $13.39
** Company posts fourth-quarter net loss of 2 cents per share vs analysts' estimate of break even per share, according to data compiled by LSEG
** Company reports product revenue of $11.65 million vs est $10.53 million
** As of last close, Eton Pharma's shares have more than tripled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。